Profile data is unavailable for this security.
About the company
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
- Revenue in SEK (TTM)2.27m
- Net income in SEK-218.33m
- Incorporated2007
- Employees97.00
- LocationQ linea ABDag Hammarskjolds Vag 52 AUPPSALA 752 37SwedenSWE
- Phone+46 184443610
- Websitehttps://www.qlinea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Luxbright AB | 4.20m | -22.23m | 110.43m | 10.00 | -- | 3.71 | -- | 26.28 | -0.24 | -0.24 | 0.0454 | 0.2641 | 0.104 | -- | 4.14 | 420,270.00 | -55.02 | -61.39 | -62.23 | -70.36 | -134.43 | -577.85 | -528.90 | -2,529.11 | 0.7743 | -4,539.47 | 0.0084 | -- | 55.58 | -- | -20.07 | -- | -- | -- |
| Dignitana AB | 86.49m | -25.27m | 112.76m | 29.00 | -- | 11.52 | -- | 1.30 | -0.3268 | -0.3268 | 1.13 | 0.1215 | 1.74 | 2.76 | 15.19 | 3,203,482.00 | -50.91 | -42.21 | -122.38 | -68.91 | 69.56 | 66.09 | -29.22 | -57.29 | 0.5202 | -9.97 | 0.609 | -- | 17.90 | 20.59 | 22.52 | -- | -15.31 | -- |
| Redsense Medical AB (publ) | 23.77m | -3.98m | 115.11m | 5.00 | -- | 3.58 | -- | 4.84 | -0.2871 | -0.2871 | 1.65 | 1.95 | 0.7524 | 7.58 | 4.18 | 4,754,400.00 | -12.58 | -18.66 | -14.51 | -20.99 | 20.47 | -2.72 | -16.72 | -46.28 | 4.00 | -89.34 | 0.00 | -- | 74.11 | 28.94 | 48.47 | -- | -23.62 | -- |
| Phase Holographic Imaging PHI AB | 9.12m | -21.81m | 119.67m | 14.00 | -- | -- | -- | 13.12 | -0.8695 | -0.8695 | 0.3634 | -0.0273 | 0.2373 | 0.6598 | 1.18 | 651,571.40 | -56.73 | -62.04 | -88.25 | -79.16 | 71.06 | 63.16 | -239.04 | -328.50 | 0.1916 | -5.61 | 1.04 | -- | 6.16 | 17.96 | 12.98 | -- | 22.76 | -- |
| Vo2 Cap Holding AB (publ) | 348.03m | -55.15m | 126.85m | 94.00 | -- | 0.7048 | -- | 0.3645 | -0.9759 | -0.9759 | 6.46 | 3.16 | 0.7992 | -- | 8.21 | 3,378,952.00 | -12.66 | -0.2564 | -17.29 | -0.3839 | 35.78 | 23.36 | -15.84 | -0.2409 | -- | -6.95 | 0.1429 | -- | -26.09 | 85.65 | -57.92 | -- | -17.96 | -- |
| Toleranzia AB | 0.00 | -7.12m | 133.86m | 11.00 | -- | 0.6564 | -- | -- | -0.0361 | -0.0361 | 0.00 | 0.7526 | 0.00 | -- | -- | 0.00 | -4.31 | -7.45 | -4.56 | -7.78 | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | 11.79 | -- | 63.90 | -- |
| Arcoma AB | 171.33m | 12.98m | 139.11m | 32.00 | 10.72 | 2.36 | 6.79 | 0.8119 | 0.9844 | 0.9844 | 12.99 | 4.48 | 1.87 | 3.48 | 7.87 | 5,526,807.00 | 14.18 | 1.12 | 24.21 | 2.01 | 38.29 | 37.66 | 7.58 | 0.7568 | 1.24 | 25.82 | 0.00 | 0.00 | 30.36 | 6.41 | 34.81 | -- | 22.75 | -- |
| Neola Medical AB | 0.00 | -9.47m | 143.11m | 7.00 | -- | 1.94 | -- | -- | -0.1508 | -0.1508 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -12.63 | -17.04 | -13.59 | -18.46 | -- | 4,237.20 | -- | -5,258.78 | -- | -- | 0.00 | -- | -- | -- | 12.97 | -- | 55.46 | -- |
| Nanexa AB | 26.91m | -66.68m | 153.34m | 19.00 | -- | 1.76 | -- | 5.70 | -0.6938 | -0.6938 | 0.2484 | 0.6411 | 0.2108 | -3.83 | 2.99 | 1,416,316.00 | -52.24 | -40.77 | -70.59 | -48.77 | 118.77 | 77.27 | -247.79 | -532.26 | 1.92 | -- | 0.0174 | -- | 925.42 | 147.00 | -30.44 | -- | 39.10 | -- |
| SpectraCure AB (publ) | 2.36m | -21.18m | 155.41m | 13.00 | -- | 1.32 | -- | 65.74 | -0.218 | -0.218 | 0.0243 | 1.21 | 0.0166 | -- | 24.63 | 157,600.00 | -14.82 | -12.75 | -15.91 | -13.62 | 442.39 | 195.30 | -895.85 | -494.40 | -- | -- | 0.0494 | -- | -3.30 | -- | 19.46 | -- | -- | -- |
| Bactiquant A/S | 13.97m | -22.52m | 165.16m | -- | -- | 15.55 | -- | 11.82 | -0.6558 | -0.6558 | 0.4064 | 0.2906 | 0.5101 | 2.94 | 5.06 | -- | -82.23 | -41.26 | -92.65 | -47.16 | -24.34 | 12.89 | -161.20 | -71.77 | 2.73 | -9.48 | 0.5326 | -- | -0.689 | -- | 7.62 | -- | -- | -- |
| Q linea AB | 2.27m | -218.33m | 205.98m | 97.00 | -- | 8.03 | -- | 90.90 | -1.87 | -1.87 | 0.0194 | 0.219 | 0.0107 | 0.1224 | 3.01 | 17,842.52 | -103.05 | -59.66 | -149.74 | -66.14 | -124.10 | -378.58 | -9,635.17 | -4,046.97 | 0.4141 | -- | 0.7825 | -- | -65.28 | 33.02 | 14.64 | -- | 41.94 | -- |
| Micropos Medical AB (publ) | 2.55m | -23.03m | 219.78m | 9.00 | -- | 14.95 | -- | 86.32 | -0.1536 | -0.1536 | 0.017 | 0.0964 | 0.1238 | 0.1034 | 2.09 | 318,247.50 | -112.02 | -64.24 | -154.79 | -82.27 | 82.20 | 114.76 | -904.59 | -767.57 | 2.73 | -- | 0.0249 | -- | 50.23 | 5.94 | -26.57 | -- | -- | -- |
| INIFY Laboratories AB | 9.43m | -51.85m | 240.07m | 26.00 | -- | 5.04 | -- | 25.47 | -1.17 | -1.17 | 0.2119 | 1.07 | 0.1164 | 2.16 | 1.83 | -- | -64.03 | -- | -64.03 | -- | 84.45 | -- | -550.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Scandinavian Medical Solutions A/S | 307.15m | 8.35m | 260.88m | 25.00 | 31.07 | 2.17 | 13.85 | 0.8494 | 0.1963 | 0.1963 | 7.22 | 2.81 | 1.38 | 1.89 | 11.35 | -- | 3.75 | -- | 6.15 | -- | 24.48 | -- | 2.72 | -- | 0.4307 | 5.54 | 0.3473 | -- | 72.98 | -- | 7.49 | -- | -- | -- |
| Boule Diagnostics AB | 563.33m | -212.52m | 279.60m | 227.00 | -- | 1.10 | -- | 0.4963 | -5.48 | -5.48 | 14.17 | 6.56 | 0.8515 | 4.58 | 3.95 | 2,470,741.00 | -32.14 | 1.67 | -48.62 | 2.40 | 45.14 | 43.50 | -37.74 | 2.04 | 0.7686 | -24.41 | 0.4116 | 42.24 | 4.24 | 6.13 | 96.24 | -9.45 | -9.74 | -- |
Data as of Nov 08 2024. Currency figures normalised to Q linea AB's reporting currency: Swedish Krona SEK
10.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2024 | 8.90m | 7.59% |
| Aktie-Ansvar ABas of 30 Jun 2024 | 1.22m | 1.04% |
| Handelsbanken Fonder ABas of 30 Sep 2024 | 680.03k | 0.58% |
| SEB Investment Management ABas of 30 Sep 2024 | 601.72k | 0.51% |
| FCG Fonder ABas of 30 Sep 2024 | 399.45k | 0.34% |
| Skandia Investment Management ABas of 30 Aug 2024 | 24.94k | 0.02% |
| Storebrand Asset Management ASas of 30 Sep 2024 | 17.00k | 0.02% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 598.00 | 0.00% |
| Danske Bank A/S (Investment Management)as of 31 Oct 2024 | 330.00 | 0.00% |
| AXA Investment Managers (Paris) SAas of 31 Oct 2023 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
